BioSpace News Archive

The denture disinfectants market survey offers insights into chief growth drivers and restrains impacting the overall growth trajectory.

The Government of Canada, through its COVID-19 Immunity Task Force and Vaccine Surveillance Reference Group, is investing approximately $800,000 for a study that aims to further improve Canada’s identification and response to adverse events people may experience following COVID-19 vaccination across 10 provinces.

LAVA Therapeutics N.V., a biotechnology company focused on developing bispecific gamma-delta T cell engagers to transform the treatment of cancer, announced dosing of the first patient in the company’s Phase 1/2a clinical trial of LAVA-051 in patients with relapsed and/or refractory chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia.

Ionis Pharmaceuticals, Inc. announced that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc to increase the delivery capabilities of Ionis’ advanced LIgand Conjugated Antisense medicines.

Gennao Bio today announced the appointments of Chris Duke as chief operating officer and Julie Hambleton, M.D., as director to the company’s board.

Inozyme Pharma, Inc. today announced that Gayle Gironda has been appointed as senior vice president of human resources.

GenScript® , the world’s leading life science service provider, announced today the first GenScript Gene & Cell Engineering Virtual Summit.

Everest Medicines today announced that it has entered into a strategic collaboration with Medbanks Health Technology, a pharmacy and healthcare services provider specializing in oncology.

–LabVantage LIMS 8.7 Portal provides external customer self-service access to LIMS while maintaining the laboratory’s data security– –New Portal delivers consistent and complete submission-of-work requests and improves self-supportability–

Galecto, Inc. (NASDAQ: GLTO), today announced that it has resumed recruitment in its Phase 2b GALACTIC-1 trial of GB0139 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) under a revised protocol that was submitted to the U.S. Food and Drug Administration and other regulatory bodies, including those in Australia, Germany, Spain and the United Kingdom